Invetx Bags $15M to Pioneer Animal Biopharmaceutical Development

Invetx has secured $15 million for animal biopharmaceutical development and business expansion.

FREMONT, CA: A pioneering animal health biopharmaceutical company, Invetx, has raised $15 million in Series A financing and founding partnerships with AbCellera and WuXi Biologics. This round was led by Invetx's founding investor, Anterra Capital, to drive clinical entry of the first therapeutic applicant and preclinical development of Invetx's more extensive pipeline of protein-based therapeutics. With the raised capital, the pioneering global biologics CDMO WuXi Biologics has collaborated with Invetx as an investor and a research collaborator. The company translates the biotechnology revolution that has transformed human medicine to the world of animal health. It has created a foundational network of first-in-class global partners that develop a sustainable platform for veterinary biopharmaceutical innovation.   

This round of investment will support rapid growth on multiple fronts, bringing Invetx's first pet antibody therapeutic into clinical studies, team expansion, and substantial preclinical development across the company's pipeline. The company collaborates with contract manufacturing leader WuXi Biologics to harness its global development expertise and manufacturing capabilities. Development of biologics for pet use is an untapped area that has significant global potential, standing to benefit from decades of investment into highly efficient technologies across the human drug development lifecycle. WuXi Biologics is thrilled to team-up with Invetx to harness its joint expertise and bring a new generation of treatments to the animal health industry.

Invetx is developing the world's premier biotechnology platform for protein-based therapeutics in animal health to revolutionize standards of care in veterinary medicine. The Invetx team of extremely experienced R&D pioneers from both human biotech and animal health domains are backed by best-in-class biotechnology partners and an extensive network of veterinary scientists, industry experts, and clinicians.